Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04084678 · ClinicalTrials.gov registry record · Phase 3
Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects
A Phase 3 study, sponsored by United Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 10
- Enrollment target
NCT04084678 is a Phase 3 study that was terminated before completion, run by United Therapeutics. The registered enrollment target is 10 participants.
The verdict
NCT04084678, a Phase 3 study, was terminated before completion, sponsored by United Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 10 participants
- Enrollment target
Study Summary
Study ROR-PH-302, ADVANCE CAPACITY, was designed to evaluate the effects of ralinepag therapy on exercise capacity as assessed by change in peak oxygen consumption (VO2) derived from cardiopulmonary exercise testing (CPET) after 28 weeks of treatment.
Interventions
- DRUG Placebo
- DRUG Ralinepag
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-01-20 |
| Est. Completion | 2023-04-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04084678
The ClinicalTrials.gov registry entry for NCT04084678 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04084678 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04084678 about?
NCT04084678 is a clinical study titled "Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects". Study ROR-PH-302, ADVANCE CAPACITY, was designed to evaluate the effects of ralinepag therapy on exercise capacity as assessed by change in peak oxygen consumption (VO2) derived from cardiopulmonary exercise testing (CPET) after 28 weeks of treatment.
What is the current status of trial NCT04084678?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 10 participants. The study started on 2021-01-20. Estimated completion is 2023-04-12.
What interventions are being tested in trial NCT04084678?
The interventions under investigation include: Placebo (DRUG), Ralinepag (DRUG).
Who is sponsoring clinical trial NCT04084678?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.